TD Waterhouse Canada Inc. Sells 1,644 Shares of Elevance Health, Inc. $ELV

TD Waterhouse Canada Inc. trimmed its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 19.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,756 shares of the company’s stock after selling 1,644 shares during the period. TD Waterhouse Canada Inc.’s holdings in Elevance Health were worth $2,368,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Physician Wealth Advisors Inc. boosted its holdings in shares of Elevance Health by 331.6% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after buying an additional 63 shares in the last quarter. Activest Wealth Management boosted its holdings in shares of Elevance Health by 66.7% during the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after buying an additional 34 shares in the last quarter. Rossby Financial LCC boosted its holdings in shares of Elevance Health by 110.0% during the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after buying an additional 44 shares in the last quarter. Motco boosted its holdings in shares of Elevance Health by 334.8% during the 3rd quarter. Motco now owns 100 shares of the company’s stock worth $32,000 after buying an additional 77 shares in the last quarter. Finally, True Wealth Design LLC boosted its holdings in shares of Elevance Health by 431.8% during the 3rd quarter. True Wealth Design LLC now owns 117 shares of the company’s stock worth $38,000 after buying an additional 95 shares in the last quarter. 89.24% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Wells Fargo & Company cut their price target on Elevance Health from $424.00 to $391.00 and set an “overweight” rating on the stock in a report on Friday, January 30th. Sanford C. Bernstein cut their target price on Elevance Health from $431.00 to $409.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Royal Bank Of Canada cut Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 target price on the stock. in a report on Tuesday, February 3rd. Leerink Partners increased their target price on Elevance Health from $350.00 to $357.00 and gave the stock a “market perform” rating in a report on Thursday, January 29th. Finally, Wolfe Research set a $425.00 target price on Elevance Health and gave the stock an “outperform” rating in a report on Thursday, January 8th. Eleven analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Elevance Health has a consensus rating of “Hold” and a consensus target price of $378.30.

Trending Headlines about Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q1 results beat and company raised full?year outlook: Elevance reported Q1 EPS of $12.58 and revenue of $49.49B, topping consensus and saying results reflected improving claims trends; management raised its full?year adjusted EPS guidance. Elevance Q1 Results & Guidance
• Positive Sentiment: Beat driven by investment income: Net investment income jumped ~29.7%, which materially lifted EPS and helped offset weaker membership and higher medical costs in the quarter. Zacks: ELV Beats on Net Investment Income
• Positive Sentiment: Dividend maintained/increased visibility: Elevance declared a quarterly dividend of $1.72 per share (record June 10), supporting income investors and signaling cash?flow confidence.
• Neutral Sentiment: Earnings call and detail resources available: Management commentary and the full Q1 call transcript provide detail on claims trends, membership dynamics and cost controls for deeper due diligence. Earnings Call Transcript
• Negative Sentiment: Underlying operational headwinds: Management noted membership declines and elevated medical costs; those trends limit margin upside and create execution risk even as investment income buoyed EPS. Key Metrics Analysis
• Negative Sentiment: Shareholder litigation/investigation announced: Kirby McInerney LLP opened an investigation into potential securities law violations involving the company or senior management — a governance/legal overhang that can pressure the stock. Investor Alert: Investigation
• Negative Sentiment: Guidance vs. Street expectations: Although the company said it raised guidance, its updated FY EPS range remains well below some analyst consensus figures, leaving room for disappointment and analyst revisions.

Elevance Health Price Performance

Shares of ELV opened at $326.32 on Thursday. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $432.93. The business’s fifty day moving average is $308.80 and its 200 day moving average is $331.56. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. The stock has a market cap of $71.68 billion, a P/E ratio of 12.99, a P/E/G ratio of 1.81 and a beta of 0.49.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. The company had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.Elevance Health’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same period last year, the business earned $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Sell-side analysts anticipate that Elevance Health, Inc. will post 25.75 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be given a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s dividend payout ratio is presently 27.39%.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.